• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

A study about the anticancer agent-related gene change in the human lung cancer orthotopic implantation model

Research Project

Project/Area Number 18591552
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Thoracic surgery
Research InstitutionDepartment of Clinical Research, National Hospital Organization Tokushima National Hospital (2007)
The University of Tokushima (2006)

Principal Investigator

MIYOSHI Takanori  Department of Clinical Research, National Hospital Organization Tokushima National Hospital, 独立行政法人国立病院機構・徳島病院臨床研究部, Head physician (20346612)

Co-Investigator(Kenkyū-buntansha) KONDO Kazuya  University of Tokushima, Department of Medicine, Professor (10263815)
TOBA Hiroaki  NHO Tokushima Hospital, University of Tokushima Hospital, Medical staff (40403745)
Project Period (FY) 2006 – 2007
Project Status Completed (Fiscal Year 2007)
Budget Amount *help
¥3,950,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2007: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2006: ¥2,000,000 (Direct Cost: ¥2,000,000)
Keywordsesophageal cancer / thyroid anaplastic carcinoma / lung cancer / orthotopic implantation model / lymph node metastasis / metastasis related gene / anti cancer agent related gene / TaqMan Low Density Array
Research Abstract

The human lung cancer orthotopic implantation model uses an SCID mouse and forms the primary tumor and succeeds in making the mediastinal lymph node metastasis model. It is the rare for the cancer model. Therefore, using ACT-1 cells (anaplastic carcinoma of thyroid) and YES-3 cells (esophageal cancer), we made the human cancer cell models with SCID mouse. The method fixes the SCID mouse in face up position under the anesthesia. We shut stomach after adding about 1.5cm horizontal incision to an epigastric region in the case of the gullet and perform an operation and expose the esophagus, and having injected cell suspension 10 μ ml which we prepared beforehand in the esophageal muscular layer with 30G needle. We shut wound after adding horizontal incision to a cervix in the case of the thyroid gland and expose the trachea and confirm the thyroid gland, and having injected cell suspension 10 μ ml in the thyroid gland with 30G needle. Four weeks later, the model formed micro-metastases in … More six weeks, and formed macro-metastases in eight weeks. In addition, the thyroid carcinoma did neoplasia in the thyroid gland in injection six weeks and understood that caused mediastinum lymph node metastasis in eight weeks. Because it was able to reproduce lymph node metastasis of the cancer of the human esophageal cancer in the mouse, each thyroid carcinoma, there was it of contribution preparations to the magazine of the cancer connection now because I perform these supplementary examinations, and it was possible for a course in correct time in progress to make the metastasis from neoplasia.
In addition, we performed the anticancer agent dosage, and it was the examination of the anticancer agent in the tumor-related gene change, but we decided to perform it in a model under the skin before aforementioned place transplant model, and making of, 5-FU and CDDP administered a tumor to the SCID mouse subcutaneous about a YES-3 cell between things of resistant acquisition during the dosage. We gathered each tumor organization at the time of effect expression the anticancer agent dosage ago at resistant acquisition time. For genetic norrowing, I searched it in DNA array. It was suggested that PI3K/Akt signaling pathway was related to resistant acquisition. I perform the anticancer agent dosage with the aforementioned place transplant model mentioned above and am going to perform a study about the anticancer agent connection gene change in the orthotopic implantation model. Less

Report

(3 results)
  • 2007 Annual Research Report   Final Research Report Summary
  • 2006 Annual Research Report
  • Research Products

    (3 results)

All 2007

All Presentation (3 results)

  • [Presentation] 食道癌生検組織における5-FU代謝酵素の発現とDocetaxel併用化学療法との関連性2007

    • Author(s)
      吉田 卓弘
    • Organizer
      日本癌治療学会
    • Place of Presentation
      京都
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2007 Final Research Report Summary
  • [Presentation] The expression of the 5-FU metabolism enzyme in the esophageal cancer biopsy specimens and the relationship with the Docetaxel combination chemotherapy2007

    • Author(s)
      Takahiro Yoshida
    • Organizer
      45^<th> Annual Meeting of Japan Society of Clinical Oncology
    • Place of Presentation
      Kyoto
    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2007 Final Research Report Summary
  • [Presentation] 食道癌生検組織における5-FU代謝酵素の発現とDocetaxel併用化学療法と関連性2007

    • Author(s)
      吉田 卓弘
    • Organizer
      日本癌治療学会
    • Place of Presentation
      京都
    • Related Report
      2007 Annual Research Report

URL: 

Published: 2006-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi